Why Did U, MRNA, ABNB Stocks Surge To 52-Week Highs Today?
π Moderna stock surged to a near five-year high of $280.80 following a strong Q3 earnings beat.
π° The company posted its first profitable quarter in two years with net income reaching $162 million.
π Revenue advanced 29% year-over-year to $1.31 billion, driven largely by international COVID-19 vaccine sales.
π¬ Analysts are optimistic about Moderna's experimental skin cancer vaccine pipeline developed in partnership with Merck.
π― Piper Sandler raised its price target to $305 and maintained an 'Overweight' rating on the stock.
π Goldman Sachs increased its price target to $195 after reviewing the improved annual forecast.
π Retail sentiment around the stock remained bullish as shares climbed 5% during the trading session.
Bullish Signals
- Moderna reported its first profitable quarter in two years with Q3 net income reaching $162 million, reversing a $200 million loss from the prior year.
- Revenue advanced 29% to $1.31 billion, supported by stronger international sales of COVID-19 vaccines.
- Analyst Piper Sandler raised its price target to $305 from $230, citing hopes for the experimental skin cancer vaccine developed with Merck.
- Goldman Sachs raised its price target to $195 following the strong earnings report and improved annual forecast.
- The stock surged to a near five-year high of $280.80, climbing 5% during the session on Monday.
Full Analysis
Moderna (MRNA) shares surged to a near five-year high of $280.80 after the biotechnology company reported its first profitable quarter in two years. The third-quarter net income reached $162 million, or $0.38 per share, driven by a 29% revenue increase to $1.31 billion supported by stronger international sales of COVID-19 vaccines.
Wall Street analysts responded positively to Moderna's financial turnaround and its experimental skin cancer vaccine pipeline developed with Merck. Piper Sandler raised its price target to $305, citing hopes for a major regulatory development by 2027, while Goldman Sachs increased its target to $195 following the strong earnings report and improved annual forecast.
Retail sentiment remained bullish as Moderna's stock climbed 5% during the session. The company's return to profitability and positive outlook on its cancer vaccine pipeline were key drivers of investor optimism, pushing the stock price significantly higher despite broader market fluctuations.